Addex Therapeutics Ltd
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $5.5M
- Price
- $3.13
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.57%
- Volume
- 9.4K
About
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
Quick stats
Shares outstanding1.8M
Computed float1.6M
Float / shares89.4%
Cash runway (months)11.6
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001574232
AI Summary
AI-generated1/29
minorneutralexecutive change
Addex Therapeutics Announces Executive Management Changes
Addex Therapeutics appointed Jean-Philippe Rocher as Head of Pharmaceutical Development and a member of Executive Management.
Dr. Rocher is a 30-year drug development veteran and former Addex chemistry platform builder, returning after retirement from spin-out Neurosterix.
Mikhail Kalinichev steps down as Head of Translational Science to focus on his role at Neurosterix; the change coincides with Addex regaining rights to its GABAB PAM program from Indivior.